The Microvesicles group of team 3 has just published 2 articles
+ COVID-19 and microvesicles
Dissemination of extreme levels of extracellular vesicle – tissue factor activity in severe COVID-19 patients
To read the full paper, head to the following link:
(Blood Advances in press available soon)
+ A new methodology to measure the procoagulant activity of microvesicles
A new hybrid immunocapture bioassay with improved reproducibility to measure tissue factor-dependent procoagulant activity of microvesicles from body fluids
Highlights
• Microvesicle-Tissue Factor (MV-TF) assays are limited by a poor reproducibility.
• A new MV-TF hybrid capture bioassay bypassing centrifugation was developed.
• CD29/CD59 capture is more efficient than centrifugation to recover MV-TF activity.
• The capture assay is more reproducible than assay isolating MV by centrifugation.
• The capture bioassay allows identifying the cellular origin of MV-TF.
To read the full paper, head to the following link:
https://doi.org/10.1016/j.thromres.2020.09.020 SMASH
You have comments, questions on this work? We’ll be happy to exchange further with you.